Breakthrough Therapy Designation for Amdizalisib 13 September 2021 07:00:08 | Reach | 13.09.21 | 07:00:08 |
HUTCHMED and AZ Initiate Phase III Trial in China 08 September 2021 11:30:00 | Reach | 08.09.21 | 11:30:00 |
HUTCHMED to Present Clinical Data at ESMO 07 September 2021 09:30:08 | Reach | 07.09.21 | 09:30:08 |
HUTCHMED Shares Included in Stock Connect Programs 06 September 2021 07:00:08 | Reach | 06.09.21 | 07:00:08 |
Grant of Share Options, and Awards under LTIP 02 September 2021 12:45:06 | RNS | 02.09.21 | 12:45:06 |
| Total Voting Rights | RNS | 31.08.21 | 09:30:01 |
| Phase Ib/II Trial of Fruquintinib & Tislelizumab | Reach | 26.08.21 | 07:00:03 |
| HUTCHMED Selected for Certain Hang Seng Indexes | Reach | 23.08.21 | 07:00:06 |
| ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION | RNS | 17.08.21 | 09:30:03 |
| HUTCHMED & Epizyme Announce TAZVERIK Collaboration | RNS | 09.08.21 | 07:00:07 |
| Total Voting Rights | RNS | 30.07.21 | 09:30:06 |
| Interim Results and Business Updates | RNS | 28.07.21 | 12:00:01 |
| Phase II Trial of ORPATHYS Initiated | Reach | 28.07.21 | 07:00:09 |
| Stabilizing Actions & End of Stabilization Period | RNS | 23.07.21 | 12:01:35 |
| Holding(s) in Company | RNS | 16.07.21 | 10:50:00 |
| Surufatinib MAA Submitted and Validated by the EMA | Reach | 16.07.21 | 07:00:03 |
| Holding(s) in Company | RNS | 14.07.21 | 09:35:01 |
| First Commercial Sale of ORPATHYS® in China | Reach | 13.07.21 | 07:00:05 |
| Full Exercise of the Over-allotment Option | RNS | 12.07.21 | 14:35:02 |
| HUTCHMED Initiates Phase I Trials of HMPL-295 | Reach | 06.07.21 | 09:30:01 |
